Parkinson's disease. Parkinson's disease
Conditions
Interventions
Intervention 1: Intervention group: This group receives the standard treatment of levodopa (levodopa/carbidopa tablet three times daily)along with lavender capsules for 8 weeks. The dose of the drug
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
55 Years to 75 Years
Inclusion criteria
Inclusion criteria: Idiopathic Parkinson's disease Age range of 55 to 75 years The onset age of the disease is less than 5 years Stages one to three of Parkinson's disease
Exclusion criteria
Exclusion criteria: The lack of physical and mental ability to answer the questions Alcohol and drug use History of systemic physical diseases such as diabetes, heart and brain stroke, heart, respiratory and kidney failure and uncontrolled blood pressure Occurrence of debilitating disease during treatment Taking a new drug due to lack of response to levodopa treatment or intolerance to levodopa if the diagnosis is primary Taking sedative drugs or drugs that interfere with lavender, such as antipsychotic drugs, monoamine oxidase inhibitors, benzodiazepines, tricyclic antidepressants, anticonvulsants, and barbiturates.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Movement signs. Timepoint: Patients are examined at the beginning of the study, week 4, week 8 and 4 weeks after stopping the drug (week 12). Method of measurement: The SPES/SCOPA questionnaire is completed by the attending physician in four stages during the treatment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Daily activities. Timepoint: Patients are examined at the beginning of the study, week 4, week 8 and 4 weeks after stopping the drug (week 12). Method of measurement: Specific Parkinson's Quality of Life Questionnaire (PDQL).;Quality of Life. Timepoint: Patients are examined at the beginning of the study, week 4, week 8 and 4 weeks after stopping the drug (week 12). Method of measurement: Specific Parkinson's Quality of Life Questionnaire (PDQL).;Motor complications. Timepoint: Patients are examined at the beginning of the study, week 4, week 8 and 4 weeks after stopping the drug (week 12). Method of measurement: Specific Parkinson's Quality of Life Questionnaire (PDQL).;Changing position. Timepoint: Patients are examined at the beginning of the study, week 4, week 8 and 4 weeks after stopping the drug (week 12). Method of measurement: Specific Parkinson's Quality of Life Questionnaire (PDQL). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactreihaneh mirshekari
Kerman University of Medical Sciences
Outcome results
None listed